SAUDI FELLOWSHIP TRAINING PROGRAM

CLINICAL PHARMACY HEMATOLOGY / ONCOLOGY PHARMACY

Final Examination

Exam Format:

The Saudi subspecialty fellowship and diplomas final written examination shall consist of one paper with 80-120 multiple-choice questions (single best answer out of four options). 10% unscored items can be added for pretesting purposes.

Passing Score:

The passing score is 70%. However, if the percentage of candidates passing the examination before final approval is less than 70%, the passing score must be lowered by one mark at a time aiming at achieving 70% passing rate or 65% passing score whichever comes first. Under no circumstances can the passing score be reduced below 65%.

Suggested References:

- The American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) updated guidelines
- National Comprehensive Cancer Network (NCCN) updated guidelines
- The American Society of Hematology and the American Society of Transplantation and Cellular Therapy (ASBMT) updated guidelines
- Infectious diseases in allogeneic Hematopoietic Stem Cell Transplantation: Prevention and Prophylaxis Strategy (AGIHO/DGHO) updated guidelines
- Multinational Association of Supportive Care in Cancer (MASCC) updated guidelines
- Professionalism and Ethics, Handbook for Residents, Practical guide, Prof. James Ware, Dr. Abdulaziz Fahad Alkaabba, Dr. Ghaiath MA Hussein, Prof. Omar Hasan Kasule, SCFHS, Latest Edition.
- Essentials of Patient Safety, SCHS, Latest Edition.

Note:

This list includes the suggested guidelines that can be reviewed by June 2026, and it is intended for use as a study aid only. SCFHS does not intend the list to imply endorsement of these specific references, nor are the exam questions necessarily taken solely from these sources.

Blueprint Outlines:

No.	Sections	Percentage
1	Breast cancer	10%
2	Gastrointestinal cancer	10%
3	Genitourinary cancer	6%
4	Gynecological cancer	7%
5	Head/Neck cancer	5%
6	Hematological diseases[1]	30%
7	Lung cancer	6%
8	Melanomas, Sarcomas	6%
9	Neurooncology	5%
10	Supportive care	15%
Total		**100%**

[1]Hematological diseases: including malignant and benign hematological disorders, lymphomas, and bone marrow transplantation

Notes:

- Blueprint distributions of the examination may differ up to +/-5% in each section.
- Percentages and content are subject to change at any time. See the SCFHS website for the most up-to-date information.
- Research, Ethics, Professionalism, and Patient Safety are incorporated within various domains.
- Results will be published within 14 business days following the last date of your examination.